Novacyt S.A
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive h… Read more
Novacyt S.A (NVYTF) - Total Liabilities
Latest total liabilities as of June 2025: $25.73 Million USD
Based on the latest financial reports, Novacyt S.A (NVYTF) has total liabilities worth $25.73 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Novacyt S.A - Total Liabilities Trend (2011–2024)
This chart illustrates how Novacyt S.A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Novacyt S.A Competitors by Total Liabilities
The table below lists competitors of Novacyt S.A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Junee Limited Ordinary Shares
NASDAQ:JUNE
|
USA | $1.04 Million |
|
Bewi Asa
OL:BEWI
|
Norway | Nkr696.50 Million |
|
Zuari Agro Chemicals Limited
NSE:ZUARI
|
India | ₹15.46 Billion |
|
Metal Sky Star Acquisition Corporation Ordinary shares
NASDAQ:MSSA
|
USA | $7.85 Million |
|
Q32 Bio Inc
NASDAQ:QTTB
|
USA | $76.23 Million |
|
Healthcare Integrated Technologies Inc
PINK:HITC
|
USA | $849.40K |
Liability Composition Analysis (2011–2024)
This chart breaks down Novacyt S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Novacyt S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Novacyt S.A (2011–2024)
The table below shows the annual total liabilities of Novacyt S.A from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $22.75 Million | -51.15% |
| 2023-12-31 | $46.57 Million | +81.32% |
| 2022-12-31 | $25.68 Million | -38.67% |
| 2021-12-31 | $41.88 Million | -49.88% |
| 2020-12-31 | $83.57 Million | +493.86% |
| 2019-12-31 | $14.07 Million | +26.14% |
| 2018-12-31 | $11.16 Million | +37.94% |
| 2017-12-31 | $8.09 Million | -25.14% |
| 2016-12-31 | $10.80 Million | +122.45% |
| 2015-12-31 | $4.86 Million | +2.56% |
| 2014-12-31 | $4.74 Million | +555.79% |
| 2013-12-31 | $722.07K | -63.13% |
| 2012-12-31 | $1.96 Million | -2.26% |
| 2011-12-31 | $2.00 Million | -- |